FLUIDIA has developed a proprietary technology ModiQuant Technology that makes possible an easy, quantitative and accurate analysis of native and PTM forms of protein biomarkers in order to improve diagnosis, prognosis and therapy monitoring of human diseases.

 

The following PTM can be assessed by ModiQuant Technology

• Phosphorylation
• Glycosylation
• Ubiquiotination
• S-nitrosylation
• Methylation
• N-acetylation
• Lipidation
• Proteolytic cleavage

ModiQuant allows quantitative assessment of a defined protein biomarker in its native and PTM form may be applied to any protein biomarker if

• The entire polypeptide sequence is known
• The type of PTM and the site in which the PTM occurs are known
• It is possible to acquire or produce monoclonal antibodies or aptamers specifically designed to recognize the PTM sequence

 

The cost for the R&D needed for the setup of a single immunoassay (one candidate biomarker in its native and PTM form) may vary according to the complexity of the project and the number of candidate biomarkers. Contact us for further details.